379 related articles for article (PubMed ID: 36550105)
1. Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis.
Uaprasert N; Pitakkitnukun P; Tangcheewinsirikul N; Chiasakul T; Rojnuckarin P
Blood Cancer J; 2022 Dec; 12(12):173. PubMed ID: 36550105
[TBL] [Abstract][Full Text] [Related]
2. Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysis.
Martins-Branco D; Nader-Marta G; Tecic Vuger A; Debien V; Ameye L; Brandão M; Punie K; Loizidou A; Willard-Gallo K; Spilleboudt C; Awada A; Piccart M; de Azambuja E
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3075-3080. PubMed ID: 35867203
[TBL] [Abstract][Full Text] [Related]
3. Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination.
Guven DC; Sahin TK; Akın S; Uckun FM
Oncologist; 2022 Apr; 27(4):e357-e361. PubMed ID: 35274729
[TBL] [Abstract][Full Text] [Related]
4. The effectiveness of the first dose COVID-19 booster vs. full vaccination to prevent SARS-CoV-2 infection and severe COVID-19 clinical event: a meta-analysis and systematic review of longitudinal studies.
Xu J; Lan X; Zhang L; Zhang X; Zhang J; Song M; Liu J
Front Public Health; 2023; 11():1165611. PubMed ID: 37325336
[TBL] [Abstract][Full Text] [Related]
5. Kinetics of cellular and humoral immunogenicity and effectiveness of SARS-CoV-2 booster vaccination in hematologic neoplasms.
Jiménez M; Fernández-Naval C; Navarro V; Novoa S; Martinez-Gallo M; Medina D; Andrés C; Antón A; Peralta S; Pujadas G; Hernández C; Pagès C; Roldán E; Pumarola T; Gironella M; Ruiz-Camps I; Martínez-Gómez X; Valcárcel D; Hernández M; Bosch F; Crespo M; Esperalba J; Abrisqueta P
Am J Hematol; 2023 Aug; 98(8):1204-1213. PubMed ID: 37151135
[TBL] [Abstract][Full Text] [Related]
6. Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study.
Corradini P; Agrati C; Apolone G; Mantovani A; Giannarelli D; Marasco V; Bordoni V; Sacchi A; Matusali G; Salvarani C; Zinzani PL; Mantegazza R; Tagliavini F; Lupo-Stanghellini MT; Ciceri F; Damian S; Uccelli A; Fenoglio D; Silvestris N; Baldanti F; Piaggio G; Ciliberto G; Morrone A; Locatelli F; Sinno V; Rescigno M; Costantini M;
Clin Infect Dis; 2023 Feb; 76(3):e426-e438. PubMed ID: 35607769
[TBL] [Abstract][Full Text] [Related]
7. A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies.
Noori M; Azizi S; Abbasi Varaki F; Nejadghaderi SA; Bashash D
Int Immunopharmacol; 2022 Sep; 110():109046. PubMed ID: 35843148
[TBL] [Abstract][Full Text] [Related]
8. Vaccination for SARS-CoV-2 in Hematological Patients.
Riccardi N; Falcone M; Yahav D
Acta Haematol; 2022; 145(3):257-266. PubMed ID: 35220303
[TBL] [Abstract][Full Text] [Related]
9. Characterization of post-vaccination SARS-CoV-2 T cell subtypes in patients with different hematologic malignancies and treatments.
Pfannes R; Pierzchalski A; Maddalon A; Simion A; Zouboulis CC; Behre G; Zenclussen AC; Westphal S; Fest S; Herberth G
Front Immunol; 2023; 14():1087996. PubMed ID: 37187728
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis.
Becerril-Gaitan A; Vaca-Cartagena BF; Ferrigno AS; Mesa-Chavez F; Barrientos-Gutiérrez T; Tagliamento M; Lambertini M; Villarreal-Garza C
Eur J Cancer; 2022 Jan; 160():243-260. PubMed ID: 34794855
[TBL] [Abstract][Full Text] [Related]
11. Determinants of humoral immune response to SARS-CoV-2 vaccines in solid cancer patients: A systematic review and meta-analysis.
Wankhede D; Grover S; Hofman P
Vaccine; 2023 Mar; 41(11):1791-1798. PubMed ID: 36792435
[TBL] [Abstract][Full Text] [Related]
12. Humoral and cellular immune responses on SARS-CoV-2 vaccines in patients with anti-CD20 therapies: a systematic review and meta-analysis of 1342 patients.
Schietzel S; Anderegg M; Limacher A; Born A; Horn MP; Maurer B; Hirzel C; Sidler D; Moor MB
RMD Open; 2022 Feb; 8(1):. PubMed ID: 35115385
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.
Schrezenmeier E; Bergfeld L; Hillus D; Lippert JD; Weber U; Tober-Lau P; Landgraf I; Schwarz T; Kappert K; Stefanski AL; Sattler A; Kotsch K; Dörner T; Sander LE; Budde K; Halleck F; Kurth F; Corman VM; Choi M
Front Immunol; 2021; 12():690698. PubMed ID: 34276681
[TBL] [Abstract][Full Text] [Related]
14. Cellular and humoral immune response to SARS-CoV-2 vaccination and booster dose in immunosuppressed patients: An observational cohort study.
Yang LM; Costales C; Ramanathan M; Bulterys PL; Murugesan K; Schroers-Martin J; Alizadeh AA; Boyd SD; Brown JM; Nadeau KC; Nadimpalli SS; Wang AX; Busque S; Pinsky BA; Banaei N
J Clin Virol; 2022 Aug; 153():105217. PubMed ID: 35714462
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review.
Piechotta V; Mellinghoff SC; Hirsch C; Brinkmann A; Iannizzi C; Kreuzberger N; Adams A; Monsef I; Stemler J; Cornely OA; Bröckelmann PJ; Skoetz N
Blood Cancer J; 2022 May; 12(5):86. PubMed ID: 35641489
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of COVID-19 Booster Vaccines in Patients with Hematologic Malignancies: Experiences in a Real-World Scenario.
Krekeler C; Reitnauer L; Bacher U; Khandanpour C; Steger L; Boeckel GR; Klosner J; Tepasse PR; Kemper M; Hennies MT; Mesters R; Stelljes M; Schmitz N; Kerkhoff A; Schliemann C; Mikesch JH; Schmidt N; Lenz G; Bleckmann A; Shumilov E
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428605
[TBL] [Abstract][Full Text] [Related]
17. Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial.
Bonelli M; Mrak D; Tobudic S; Sieghart D; Koblischke M; Mandl P; Kornek B; Simader E; Radner H; Perkmann T; Haslacher H; Mayer M; Hofer P; Redlich K; Husar-Memmer E; Fritsch-Stork R; Thalhammer R; Stiasny K; Winkler S; Smolen JS; Aberle JH; Zeitlinger M; Heinz LX; Aletaha D
Ann Rheum Dis; 2022 May; 81(5):687-694. PubMed ID: 35027397
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies.
Haggenburg S; Hofsink Q; Rutten CE; Nijhof IS; Hazenberg MD; Goorhuis A
Semin Hematol; 2022 Oct; 59(4):192-197. PubMed ID: 36805887
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and Safety of SpikoGen, an Adjuvanted Recombinant SARS-CoV-2 Spike Protein, as a Heterologous Third Booster Dose in Kidney Transplant Patients: A Single-arm Clinical Trial.
Nafar M; Mostafaloo N; Firouzan A; Poorrezagholi F; Samadian F; Dalili N; Barati S; Anjidani N; Kafi H; Shahpari R; Bayat M; Kianipour S; Samavat S
Clin Ther; 2022 Dec; 44(12):1566-1576. PubMed ID: 36402595
[TBL] [Abstract][Full Text] [Related]
20. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
